Literature DB >> 31538314

Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy.

Y P Hai1, A C H Lee1, L Frommer1, T Diana1, G J Kahaly2.   

Abstract

PURPOSE: Immunohistochemistry of orbital tissues offers a correlation between the microscopic changes and macroscopic clinical manifestation of Graves' orbitopathy (GO). Summarizing the participation of different molecules will help us to understand the pathogenesis of GO.
METHODS: The pertinent and current literature on immunohistochemistry of human orbital tissue in GO was reviewed using the NCBI PubMed database.
RESULTS: 33 articles comprising over 700 orbital tissue samples were included in this review. The earliest findings included the demonstration of HLA-DR and T cell (to a lesser extent B cell) markers in GO orbital tissues. Subsequent investigators further contributed by characterizing cellular infiltration, confirming the presence of HLA-DR and TSHR, as well as revealing the participation of cytokines, growth factors, adhesion molecules and miscellaneous substances. HLA-DR and TSHR are over-expressed in orbital tissues of GO patients. The inflammatory infiltration mainly comprises CD4 + T cells and macrophages. Cytokine profile suggests the importance of Th1 (especially in early active phase) and Th17 immunity in the pathogenesis of GO. Upregulation of proinflammatory/profibrotic cytokines, adhesion molecules and growth factors finally culminate in activation of orbital fibroblasts and perpetuation of orbital inflammation. The molecular status of selected parameters correlates with the clinical presentation of GO.
CONCLUSION: Further investigation is warranted to define precisely the role of different molecules and ongoing search for new players yet to be discovered is also important. Unfolding the molecular mechanisms behind GO will hopefully provide insights into the development of novel therapeutic strategies and optimize our clinical management of the disease.

Entities:  

Keywords:  Cytokine; Graves’ orbitopathy; Human leukocyte antigen; Immunohistochemistry; Orbital tissue; TSH receptor

Year:  2019        PMID: 31538314     DOI: 10.1007/s40618-019-01116-4

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  59 in total

1.  Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy.

Authors:  L van Steensel; D Paridaens; M van Meurs; P M van Hagen; W A van den Bosch; R W A M Kuijpers; H A Drexhage; H Hooijkaas; W A Dik
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

2.  Orbital fibroblasts of Graves' orbitopathy stimulated with proinflammatory cytokines promote B cell survival by secreting BAFF.

Authors:  Fen Tang; Xiaoqing Chen; Yuxiang Mao; Shangtao Wan; Siming Ai; Huasheng Yang; Guangming Liu; Yusha Zou; Miaoli Lin; Liang Dan
Journal:  Mol Cell Endocrinol       Date:  2017-01-10       Impact factor: 4.102

3.  The expression of interleukin-15 and interleukin-17 in tears and orbital tissues of Graves ophthalmopathy patients.

Authors:  Qun Chen
Journal:  J Cell Biochem       Date:  2018-12-19       Impact factor: 4.429

4.  Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy.

Authors:  A P Weetman; S Cohen; K C Gatter; P Fells; B Shine
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

5.  Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor.

Authors:  R W Valyasevi; D Z Erickson; D A Harteneck; C M Dutton; A E Heufelder; S C Jyonouchi; R S Bahn
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

6.  Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors:  Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2014-12-15       Impact factor: 5.958

7.  Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy.

Authors:  G Kahaly; C Hansen; B Felke; H P Dienes
Journal:  Clin Immunol Immunopathol       Date:  1994-10

8.  Analysis of orbital T cells in thyroid-associated ophthalmopathy.

Authors:  G Förster; E Otto; C Hansen; K Ochs; G Kahaly
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

9.  Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.

Authors:  Reed Ayabe; Dan B Rootman; Catherine J Hwang; Ami Ben-Artzi; Robert Goldberg
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2014 Sep-Oct       Impact factor: 1.746

10.  Disturbances of modulating molecules (FOXP3, CTLA-4/CD28/B7, and CD40/CD40L) mRNA expressions in the orbital tissue from patients with severe graves' ophthalmopathy.

Authors:  Przemyslaw Pawlowski; Natalia Wawrusiewicz-Kurylonek; Anja Eckstein; Joanna Reszec; Wlodzimierz Luczynski; Kristian Johnson; Adam Kretowski; Alina Bakunowicz-Lazarczyk; Maria Gorska; Jacek Szamatowicz; Lech Chyczewski; Janusz Mysliwiec
Journal:  Mediators Inflamm       Date:  2015-01-12       Impact factor: 4.711

View more
  14 in total

1.  Modulating TSH Receptor Signaling for Therapeutic Benefit.

Authors:  Gerd Krause; Anja Eckstein; Ralf Schülein
Journal:  Eur Thyroid J       Date:  2020-11-23

2.  Autoimmunity in Human CE: Correlative with The Fertility Status of The CE Cyst.

Authors:  E A El Saftawy; A Abdelraouf; M A Elsalam; P Zakareya; A Fouad; E A Albadawi; A H S Abobakr Ali; N M Amin
Journal:  Helminthologia       Date:  2022-05-04       Impact factor: 1.176

3.  Editorial: Mechanisms and Novel Therapies in Graves' Orbitopathy: Current Update.

Authors:  Huifang Zhou; Ilaria Muller; Kelvin Kam-Lung Chong; Marian Ludgate; Sijie Fang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-29       Impact factor: 6.055

4.  Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial.

Authors:  Elena Hoppe; Alan Chun Hong Lee; David Hoppe; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-07-02

5.  Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.

Authors:  Alan Chun Hong Lee; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-08-10

Review 6.  Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application.

Authors:  Jan Längericht; Irene Krämer; George J Kahaly
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-14       Impact factor: 3.565

Review 7.  Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves' Orbitopathy.

Authors:  Augustine George; Tanja Diana; Jan Längericht; George J Kahaly
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-02       Impact factor: 5.555

8.  Simultaneous detection of feline parvovirus and feline bocavirus using SYBR Green I-based duplex real-time polymerase chain reaction.

Authors:  Yong Wang; Yang Pan; Junhuang Wu; Xinxin Tong; Jianfei Sun; Fazhi Xu; Bangzhao Cheng; Yongdong Li
Journal:  3 Biotech       Date:  2021-08-06       Impact factor: 2.406

Review 9.  Management of Graves Thyroidal and Extrathyroidal Disease: An Update.

Authors:  George J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

Review 10.  IgG4 as a Biomarker in Graves' Orbitopathy.

Authors:  Michał Olejarz; Ewelina Szczepanek-Parulska; Daniela Dadej; Nadia Sawicka-Gutaj; Remigiusz Domin; Marek Ruchała
Journal:  Mediators Inflamm       Date:  2021-06-10       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.